- Pro to the question "Should Marijuana Be a Medical Option?"
“In its crude herbal form, No. As a prescription medicine standardized in composition, formulation, and dose, administered by means of appropriate (non-smoked) delivery systems, and tested in rigorous preclinical and clinical studies, Yes.”
Mark Rogerson, Press & PR spokesman for GW Pharmaceuticals, email to ProCon.org, May 19, 2005
- Theoretical Expertise Ranking:
Individuals and organizations that do not fit into the other star categories.
“GW is a pharmaceutical company developing a portfolio of prescription medicines derived from cannabis to meet patient needs in a wide variety of indications. GW’s clinical research has initially focussed on Multiple Sclerosis and neuropathic pain and has extended into Spinal Cord Injury, Cancer Pain and rheumatoid arthritis. The Company plans to continue to extend its research programme into new areas, part of which will be achieved via the Cannabinoid Research Institute (CRI), a wholly owned division of GW that conducts exploratory research.”
“FAQ,” GW Pharmaceuticals website (accessed Aug. 14, 2007)
“Our vision is to be the global leaders in prescription cannabinoid and botanical medicines, through the rapid cost-effective development of pharmaceutical products which address clear patient needs.”
“Home,” GW Pharmaceuticals website (accessed Aug. 14, 2007)
- U.K. Corporation
- Quoted in: